ITI is a program of The Task Force for Global Health.
Egyptian medical papyrus dating back to circa 1500 BC and discovered in the late 1800s recorded the prevalence of trachoma in the region during the time of inscription. Research from the 1960s indicated continued prevalence in several governorates. Even though the Ministry of Health undertook large scale antibiotic treatment programs in targeted areas, research in the 1990s and 2000s pointed to the need for more robust data and comprehensive trachoma program services.
In 2001, ITI provided antibiotics for distribution in Al Menufiya governorate.
In 2015, the Egypt trachoma control program initiated trachoma prevalence surveys using the GTMP platform in four districts suspected to be endemic for trachoma. Out of the four districts surveyed in Al Minya and Beni Suwayf governorates, three were found to have TF1-9 prevalence over 10% and one district between 5-9.9%. The prevalence data indicated the need for the implementation of the SAFE strategy for trachoma control and elimination in these four districts.
The national trachoma program convened a meeting of existing and potential partners of the national program to discuss SAFE planning in October 2016. A funding proposal was developed based on plans drafted at the meeting, and Sightsavers have committed funding to launch MDAs in Dir Mowaas and Al Mattay districts of Al Minya governorate in 2017.
Up to 29 districts are suspected endemic for trachoma and require mapping.
CURRENT IMPLEMENTATION STATUS
Implementation of trachoma MDA and the SAFE strategy will begin in late 2017/early 2018, with funding support from Sightsavers and technical support from KCCO, ITI, the Nourseen Foundation and other in-country partners.
Zithromax® Shipments by Year